Quanta Pharma Retatrutide 30mg
Original price was: $175.00.$155.00Current price is: $155.00.
Retatrutide 30mg
Triple Agonist
Lyophilized Vial
~6 Days
FREE SHIPPING
On orders over £200
✓
Research Grade
UK Fast Dispatch
Research Verified
Description
IN SHORT
Quanta Pharma Retatrutide 30mg is a synthetic triple agonist peptide studied for activity at the GLP-1, GIP and glucagon receptor pathways. This research compound is supplied as a lyophilized 30mg vial for controlled laboratory research.
Quanta Pharma Retatrutide 30mg is a synthetic peptide compound studied for activity at three receptor pathways: GLP-1, GIP and glucagon. This Retatrutide 30mg peptide is supplied as a lyophilized vial from Quanta Pharma for laboratory research.
Retatrutide’s triple-receptor activity makes it relevant to research involving metabolic signalling, receptor pharmacology, energy metabolism and related physiological pathways. The 30mg vial provides a defined quantity of compound for controlled research applications.
Retatrutide 30mg Specifications
Retatrutide
Triple Agonist
30mg/vial
Lyophilized
~6 Days
2–8°C
Retatrutide 30mg by Quanta Pharma
Lyophilized Retatrutide supplied in a 30mg vial for laboratory research. Researchers should review the applicable product documentation, safety information and storage requirements before handling this material.
Retatrutide Research Benefits
- Triple receptor activity – Retatrutide is studied for activity at GLP-1, GIP and glucagon receptor pathways.
- GLP-1 receptor research – Investigated for activity involving the glucagon-like peptide-1 receptor pathway.
- GIP receptor research – Studied alongside GLP-1 and glucagon pathways to investigate combined receptor signalling.
- Glucagon receptor research – Investigated for its role in metabolic and energy-related signalling pathways.
- Metabolic research – Studied in controlled laboratory research involving metabolic regulation and related physiological pathways.
How Retatrutide Works
Retatrutide is a synthetic peptide compound studied as an agonist at three receptor pathways: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and the glucagon receptor.
This triple-receptor profile distinguishes Retatrutide from compounds that primarily target one or two of these pathways. Laboratory research can examine how simultaneous activity across these receptor systems affects metabolic signalling and related biological processes.
Research involving Retatrutide may investigate receptor activity, intracellular signalling, energy metabolism and other pathways under controlled laboratory conditions.
Retatrutide 30mg vs Tirzepatide vs Semaglutide
Semaglutide is primarily studied for activity at the GLP-1 receptor, while Tirzepatide is studied for activity at both GLP-1 and GIP receptors. Retatrutide is investigated for activity across GLP-1, GIP and glucagon receptor pathways.
The additional glucagon receptor activity makes Retatrutide 30mg relevant to research examining triple-receptor signalling and metabolic pathways.
Retatrutide 30mg UK
Retatrutide 30mg is supplied as a lyophilized research compound in a 30mg vial. For researchers looking for Retatrutide 30mg in the UK, this product page provides information about the compound, format, quantity and stated storage requirements.
This Retatrutide 30mg vial is supplied for laboratory research purposes. Applicable product documentation and relevant regulatory requirements should be reviewed before use.
For Laboratory Research Use Only
NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.
This material is supplied exclusively for laboratory research purposes. It is not intended for human consumption, self-administration, diagnosis, treatment or prevention of disease.
Researchers should consult the applicable product documentation, safety information and local regulations before handling or working with this material.





Reviews
There are no reviews yet.